Article Text

Download PDFPDF
Letter in response to Tashkin et al: limited generalisability of uplift findings to clinical practice
  1. Steven Walker1,2,
  2. James Fingleton1,2,3,
  3. Mark Weatherall2,4,
  4. Richard Beasley1,2,3,4
  1. 1 Medical Research Institute of New Zealand, Wellington, New Zealand
  2. 2 Capital & Coast District Health Board, Wellington, New Zealand
  3. 3 Victoria University of Wellington, Wellington, New Zealand
  4. 4 University of Otago Wellington, Wellington, New Zealand
  1. Correspondence to Professor Richard Beasley, Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand; Richard.Beasley{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We appreciate the comments made by Tashkin et al 1 regarding the limited generalisability of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) findings.2 In response, the sample we studied was not designed to be representative of the general chronic obstructive pulmonary disease (COPD) population, but rather the subgroup of patients with severe COPD who are likely to be at greatest risk of serious cardiovascular events. Second, the derived data presented from the …

View Full Text


  • Contributors SW and JF undertook the data collection that was analysed by MW. All authors contributed to both the drafting of the manuscript and this letter.

  • Competing interests RB has been a member of the GlaxoSmithKline (NZ) advisory board, consulted for Cytos Biotechnology and Pharmaxis, received research grants from AstraZeneca, Cephalon, Chiesi, Genentech, GlaxoSmithKline and Novartis, and payment for lectures or support to attend meetings from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed and Otsuka Pharmaceuticals. JF has received payment for lectures or support to attend meetings from AstraZeneca, Boehringer Ingelheim and Novartis. SW and MW have no competing interests to declare.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    D P Tashkin N Metzdorf C Hallmann I Leimer T Lee M Decramer